NasdaqGS:BCRXBiotechs
A Look At BioCryst Pharmaceuticals (BCRX) Valuation After New Hereditary Angioedema Data And Conference Spotlight
BioCryst Pharmaceuticals (BCRX) is back in focus after announcing nine upcoming hereditary angioedema presentations at a major allergy conference, including positive interim ALPHA-SOLAR data for navenibart and additional real-world results for ORLADEYO.
See our latest analysis for BioCryst Pharmaceuticals.
BioCryst’s recent hereditary angioedema updates come after a mixed share price record, with a 1-day share price return of 4.43% and 7-day return of 6.54% contrasting with a year-to-date...